Point72 Europe’s Idexx Laboratories IDXX Stock Holding History

Point72 Europe’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-5,500	Closed	-$2.97M	–	147
2024 Q1	$2.97M	Buy	5,500 +5,341	+3,359%	+$2.92M	0.26%	93
2023 Q4	$88.3K	Buy	+159	New	+$74.6K	0.01%	296

Other funds holding IDXX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $13.6B AUM 7.6% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Europe's IDXX Position: Q2 2024 in Review

Point72 Europe sold out of Idexx Laboratories (IDXX) in Q2 2024, closing a stake of 5,500 shares — an estimated $2.97M sold.

Point72 Europe first reported a position in IDXX in Q4 2023 and held it in 2 quarters. The position peaked at $2.97M in Q1 2024. 1,110 funds tracked by Wall St. Rank hold IDXX as of Q2 2024.

Point72 Europe reported no remaining Idexx Laboratories position as of Q2 2024 after selling out during the quarter.
Point72 Europe sold 5,500 Idexx Laboratories shares in Q2 2024, an estimated $2.97M.
Point72 Europe first reported a position in Idexx Laboratories in Q4 2023 and held it in 2 quarters.
Point72 Europe's Idexx Laboratories position peaked at $2.97M in Q1 2024.
1,110 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2024.

Based on Point72 Europe's 13F filing for Q2 2024, filed 14 Aug 2024.